The 5-year actuarial local control rate with chemotherapy alone ranged from 53,7% (laryngeal and hypopharyngeal cancers, Tl to T4) to 91% (larynx only). Between 6% and 33% of the cases initially treated with induction chemotherapy were, after selection of the complete responders, locally controlled by exclusive chemotherapy. That is, for every 1 case locally controlled by exclusive chemotherapy, 3 to 17 cases had to be treated initially with induction chemotherapy. Salvage surgery or radiotherapy provided laryngeal preservation in 90% to 100% of cases treated by chemotherapy alone (Table 2), Toxicity in patients treated with chemotherapy alone was principally hematologic and renal. toxicity (ECOG criteria's) was observed in 14% to 21.6% of patients and grade 3 renal toxicity in 6.2% to 14% of patients. Grade 3 anemia was observed in 2.9% to 14% of patients.10-13 Higherlevels of granulocytopenia (22.6% and 29% for grades 3 and 4, respectively) were observed with the cisplatin-paclitaxel-ifosfamide (TIP) regimen.P Chemotherapy was stopped prematurely because of toxicity for approximately 1% of patients with the PF regimen.'! No chemotherapy-related deaths occurred in any of the studies.
These studies demonstrate that acceptable local control rates can be achieved with exclusive chemotherapy for complete responders in initially selected patient groups. However, for laryngeal tumors amenable to conservation surgery, other types of treatment have shown higher rates of initial local control than the PF chemotherapy-alone regimen, with laryngeal preservation comparable to that seen with exclusive chemotherapy plus salvage. The reported rates of local control with conservation laryngeal surgery for glottic carcinomatransorallaser resection or traditional open partial laryngectomy -range from 89% to 100% for Tl tumors, from 83% to 100% forT2 tumors, and from 73% to 91% forT3 tumors.!? For glottic carcinoma, reported rates of local control with radiotherapy alone range from 95% to 100% for T1 tumors. Local control rates of up to 88% have been reported for higher-stage cancers treated with chernoradiation.f In 4 of the studies, the patient groups were initially highly selected patients with tumors judged to be amenable to conservation laryngeal surgery alone for cure.IO. 12.13.15 This type of initial selection introduces surgeon-and institution-related biases. Five of the 6 publications were based on the retrospective analysis of the outcomes of selected patients and were prone to the biases of retrospective studies in general. lO -14 In these retrospective studies, the selection of patients for chemotherapy alone may have been based on "patient choice," but the attending physicians may have played a role in orienting the choice, according to tumor or patient criteria or to subjective factors. The retrospective nature of these studies also precludes analysis of patients who were lost to follow-up during or after induction chemotherapy.
In terms of initial local control, final local control, laryngeal preservation, and survival, there does not seem to be any advantage to the use of PF chemotherapy alone as compared to conservation laryngeal surgery or radiotherapy for these selected patients, and surgery and radiotherapy do not carry the same short-or longterm systemic toxicities as chemotherapy. More importantly, selecting patients amenable to chemotherapy alone for cure (complete responders) requires treating a certain number of other patients with induction chemotherapy who will not derive any benefit from it (incomplete and nonresponders). Chemotherapy alone for laryngeal preservation has the major advantage of preserving physiological voice quality, possibly even better than radiotherapy (although specific voice studies are lacking). Furthermore, chemotherapy alone preserves other treatment modalities in case of local recurrence or metachronous second primary. For now, however, chemotherapy alone has only been shown to benefit a small number of highly selected patients in a small number of studies, only one of which was conducted prospectively.P The tantalizing concept of chemotherapy alone for selected patients shows promise for the future, however. Higher rates of complete response are being reported with well-tolerated taxane-based regimens and with the association of taxanes and cetuximab.lf The development of biological markers of chemosensitivity may in the future allow pretherapy selection of patients amenable to exclusive chemotherapy, so that only potential complete responders would receive induction chemotherapy.I? Validation of the use of chemotherapy alone for laryngeal preservation will, however, require higher-level evidence with controlled clinical trials and standardized patient selection. DANA M. HARTL, MD, PHD DANIEL F. BRASNU, MD Faculte de Medecine Rene Descartes Paris V Paris, France
